HomeCompareSYN vs JEPQ

SYN vs JEPQ: Dividend Comparison 2026

SYN yields 196.08% · JEPQ yields 11.47%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYN wins by $30.7K in total portfolio value
10 years
SYN
SYN
● Live price
196.08%
Share price
$1.02
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$74.42
Full SYN calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.47%
Share price
$53.77
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.8K
Annual income
$2,269.18
Full JEPQ calculator →

Portfolio growth — SYN vs JEPQ

📍 SYN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYN + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYN pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYN
Annual income on $10K today (after 15% tax)
$16,666.67/yr
After 10yr DRIP, annual income (after tax)
$63.26/yr
JEPQ
Annual income on $10K today (after 15% tax)
$974.55/yr
After 10yr DRIP, annual income (after tax)
$1,928.80/yr
At 15% tax rate, JEPQ beats the other by $1,865.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYN + JEPQ for your $10,000?

SYN: 50%JEPQ: 50%
100% JEPQ50/50100% SYN
Portfolio after 10yr
$61.2K
Annual income
$1,171.80/yr
Blended yield
1.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYN right now

SYN
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Altman Z
-14.5
Piotroski
2/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYN buys
0
JEPQ buys
0
No recent congressional trades found for SYN or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNJEPQ
Forward yield196.08%11.47%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$76.5K$45.8K
Annual income after 10y$74.42$2,269.18
Total dividends collected$34.4K$17.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: SYN vs JEPQ ($10,000, DRIP)

YearSYN PortfolioSYN Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$20,504$9,803.92$11,967$1,146.53+$8.5KSYN
2$31,333$9,393.40$14,216$1,268.02+$17.1KSYN
3$40,234$6,707.62$16,774$1,392.20+$23.5KSYN
4$47,075$4,024.82$19,667$1,518.21+$27.4KSYN
5$52,570$2,200.55$22,925$1,645.21+$29.6KSYN
6$57,399$1,148.35$26,578$1,772.40+$30.8KSYN
7$62,003$585.89$30,656$1,899.04+$31.3KSYN
8$66,638$295.74$35,194$2,024.45+$31.4KSYN
9$71,452$148.53$40,228$2,148.01+$31.2KSYN
10$76,528$74.42$45,796$2,269.18+$30.7KSYN

SYN vs JEPQ: Complete Analysis 2026

SYNStock

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Full SYN Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this SYN vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYN vs SCHDSYN vs JEPISYN vs OSYN vs KOSYN vs MAINSYN vs XYLDSYN vs QYLDSYN vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.